We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed
Severin Schwan will be succeeded by Thomas Schinecker, head of drugmaker’s diagnostics unit
Investors had threatened to block Severin Schwan’s re-election
Two major investors say they will vote against re-election of Severin Schwan if he is proposed
Severin Schwan believes proposal is ‘counterproductive’ and will not solve supply shortages
The question is how a return to work can be made safe without a vaccine?
Severin Schwan unapologetic for outspoken criticism of state responses to coronavirus
Lack of spending means Britain trails behind in coronavirus testing, says Swiss group’s head
Process allows medics to check who has already had the disease and how far immunity is developing
Chief executive urges ‘realistic’ expectations amid threat of copycat biologic drugs
Comments come as Swiss drugmaker reports 4% increase in group sales
Swiss group calls for new rules that give patients access to innovative treatments
Chief Schwan urges pharma groups to keep innovating to stave off criticism
Swiss drugmaker raises full-year outlook on strong third-quarter sales
Drugmaker to focus on pipeline as it blames strong Swiss franc for profit drop
Swiss pharma group looks to immunotherapies to drive growth
Pharma groups face challenges merger would not address
International Edition
